Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Interest Expenses (2021 - 2023)

Historic Interest Expenses for Alaunos Therapeutics (TCRT) over the last 3 years, with Q2 2023 value amounting to $1.1 million.

  • Alaunos Therapeutics' Interest Expenses rose 4432.43% to $1.1 million in Q2 2023 from the same period last year, while for Mar 2024 it was $1.1 million, marking a year-over-year decrease of 6841.17%. This contributed to the annual value of $1.9 million for FY2023, which is 3996.88% down from last year.
  • Latest data reveals that Alaunos Therapeutics reported Interest Expenses of $1.1 million as of Q2 2023, which was up 4432.43% from $900000.0 recorded in Q1 2023.
  • Over the past 5 years, Alaunos Therapeutics' Interest Expenses peaked at $1.1 million during Q2 2023, and registered a low of $444000.0 during Q3 2021.
  • In the last 3 years, Alaunos Therapeutics' Interest Expenses had a median value of $798500.0 in 2021 and averaged $793625.0.
  • The largest annual percentage gain for Alaunos Therapeutics' Interest Expenses in the last 5 years was 8941.44% (2022), contrasted with its biggest fall of 1904.76% (2022).
  • Alaunos Therapeutics' Interest Expenses (Quarter) stood at $756000.0 in 2021, then rose by 19.05% to $900000.0 in 2022, then increased by 18.67% to $1.1 million in 2023.
  • Its Interest Expenses was $1.1 million in Q2 2023, compared to $900000.0 in Q1 2023 and $900000.0 in Q4 2022.